Value of perilesional biopsies in multiparametric magnetic resonance imaging-targeted biopsy and systematic biopsy in detection of prostate cancer: results of a prospective, non-randomized, surgeon-blinded study - Top-Institutions - MDSpire

Value of perilesional biopsies in multiparametric magnetic resonance imaging-targeted biopsy and systematic biopsy in detection of prostate cancer: results of a prospective, non-randomized, surgeon-blinded study

  • By

  • Gregor Duwe

  • Melanie Schmitteckert

  • Maximilian Haack

  • Peter Sparwasser

  • Robert Dotzauer

  • Anita Thomas

  • Igor Tsaur

  • Maximilian Peter Brandt

  • Martin Kurosch

  • Rene Mager

  • Axel Haferkamp

  • Katharina Boehm

  • Thomas Höfner

  • May 6, 2024

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urology
    • Radiology
    • Oncology

  • #2

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Urology
    • Radiology

  • #3

    Memorial University of Newfoundland - Prostate Cancer Research Group
    Memorial University of Newfoundland - Prostate Cancer Research Group

    St. John's, NL

    Key Differentiators

    • Urology
    • Radiology

  • #4

    National Cancer Institute (NCI), NIH
    National Cancer Institute (NCI), NIH

    Bethesda, MD

    Key Differentiators

    • Oncology
    • Radiology
    • Urology

  • #5

    University of Toronto - Princess Margaret Cancer Centre
    University of Toronto - Princess Margaret Cancer Centre

    Toronto, ON

    Key Differentiators

    • Urology
    • Radiology
    • Oncology

Original Source(s)

Value of perilesional biopsies in multiparametric magnetic resonance imaging-targeted biopsy and systematic biopsy in detection of prostate cancer: results of a prospective, non-randomized, surgeon-blinded study

  • by Gregor Duwe, Melanie Schmitteckert, Maximilian Haack, Peter Sparwasser, Robert Dotzauer, Anita Thomas, Igor Tsaur, Maximilian Peter Brandt, Martin Kurosch, Rene Mager, Axel Haferkamp, Katharina Boehm, Thomas Höfner

  • May 6, 2024

Related Content

PHI density prospectively improves prostate cancer detection

T2 mapping for the characterization of prostate lesions

Assessing cancer risk in the anterior part of the prostate using micro-ultrasound: validation of a novel distinct protocol